Lexaria Bioscience faces a precarious fundamental outlook characterized by a reliance on sporadic, project-based milestone payments that have failed to generate consistent revenue, as evidenced by an 88.5% year-over-year revenue decline in 2026Q2. The company'...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 13, 2026 | -$0.08-33.3% vs -$0.06 | — vs $50,000 |
Q2 2026 Apr 13, 2026 | -$0.06+40.0% vs -$0.10 | $20,000-60.0% vs $50,000 |
Q1 2026 Jan 13, 2026 | -$0.07+46.2% vs -$0.13 | — vs $100,000 |
Q4 2025 Nov 26, 2025 | -$0.13+18.8% vs -$0.16 | $174,000+27.0% vs $137,000 |
KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share.
Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share. The combined net proceeds from these two items totaled US$7.9 million. With only 2.1 million shares currently issued and outstanding, the US$7.9 million in fresh new capital plus our pre-existing cash balance represents approximately US$4.60/share in current cash on hand.
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering .
Benchmark LEXX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Lexaria Bioscience Corp. (LEXX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.24 | $5.35M | -0.33 | 52.05% | -1686% | -231.96% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $13.75 | $1.86B | -4.46 | — | — | -398.21% | — | |
| $42.79 | $3.23B | -20.77 | — | — | -102.48% | — | |
| $3.16 | $54.62M | -2.36 | — | -691.81% | — | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — |
Lexaria Bioscience Corp. (LEXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Lexaria Bioscience Corp. (LEXX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 6, 2026·SEC
Jan 28, 2026·SEC
Dec 16, 2025·SEC
Get notified when LEXX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lexaria Bioscience Corp. (LEXX) stock FAQ — growth, dividends, profitability & financials explained
Lexaria Bioscience Corp. (LEXX) reported $0.2M in revenue for fiscal year 2025. This represents a 855% increase from $0.0M in 2006.
Lexaria Bioscience Corp. (LEXX) grew revenue by 52.0% over the past year. This is strong growth.
Lexaria Bioscience Corp. (LEXX) reported a net loss of $7.7M for fiscal year 2025.
Lexaria Bioscience Corp. (LEXX) has a return on equity (ROE) of -232.0%. Negative ROE indicates the company is unprofitable.
Lexaria Bioscience Corp. (LEXX) had negative free cash flow of $7.5M in fiscal year 2025, likely due to heavy capital investments.
